Tag: University of Queensland

May 21, 2019

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that the Company's research team at the University of...
April 17, 2019

PreveCeutical Partnership Leads to Two New Patent Filings

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that the Company's research collaboration with UniQuest and The University of...
April 15, 2019

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces the Company's research team at the University of Queensland...
April 10, 2019

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H)(the "Company" or "PreveCeutical"), is pleased to announce further positive results from the preliminary screening...
April 8, 2019

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H)(the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against JCN Capital...
April 4, 2019

Retraction to News Release dated April 4, 2019

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), announces that, at the request of the Investment Industry Regulatory Organization...
March 25, 2019

PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

PreveCeutical Medical Inc. (CSE:PREV, OTC:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each...